Metastatic Synovial Sarcoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Synovial sarcoma accounts for approximately 8%–10% of all soft tissue sarcomas (STS). This malignancy can be diagnosed at any age but predominantly occurs in young adults, particularly those aged 15 to 35 years, with a higher incidence in males. Despite its relative rarity, synovial sarcoma is the third most common STS affecting the extremities. The median age at diagnosis is 35 years. The term “synovial sarcoma” is a misnomer, as the tumor does not originate from synovial tissue. It may arise near joints but never within them, and its precise cellular origin remains undefined. Additionally, synovial sarcoma can be found in regions without an apparent relationship to synovial structures, including the head and neck (<10%), thoracic and abdominal wall (<10%), and intrathoracic sites. Synovial sarcoma is an aggressive form of STS with a significant propensity for recurrence and metastasis. Approximately 50% of patients develop metastatic disease, either at initial presentation or during the disease course. The lungs are the most common site of metastasis (74%–81%), followed by lymph nodes (3%–23%) and bones (10%–20%). Surgical resection is the standard treatment for synovial sarcoma, aiming to remove the tumor along with a margin of surrounding tissue to ensure complete excision. Depending on the extent of cancer spread, this may necessitate the removal of an entire muscle or muscle group.

Thelansis’s “Metastatic Synovial Sarcoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Metastatic Synovial Sarcoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Metastatic Synovial Sarcoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Metastatic Synovial Sarcoma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Metastatic Synovial Sarcoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033